Abbott in development agreement with Axis:
This article was originally published in Clinica
Executive Summary
Axis Biochemicals (Norway) is to develop a homocysteine kit for use on Abbott's IMx immunoassay system. The marker is used for cardiovascular risk and nutritional assessment. Standard measurement methods mainly use chromatography and are not generally automated. Abbott will license an antibody clone of homocysteine to Axis and will receive royalty payments. Axis will have the rights to sell any resulting products to existing Abbott customers but Abbott has an option to distribute the assay at a later date.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.